← Back to Clinical Trials
Recruiting Phase 2 NCT06430333

NCT06430333 Sleep to Reduce Incident Depression Effectively in Peripartum

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06430333
Status Recruiting
Phase Phase 2
Sponsor Henry Ford Health System
Condition Insomnia
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2024-12-10
Primary Completion 2028-02-29

Trial Parameters

Condition Insomnia
Sponsor Henry Ford Health System
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 500
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2024-12-10
Completion 2028-02-29
Interventions
Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)Treatment-as-usual (TAU)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Perinatal depression (PND) is the most common complication in pregnancy and postpartum, which increases risk for adverse perinatal outcomes such as preterm birth, maternal suicidal thoughts, and impaired mother-infant bonding. Insomnia often precedes PND cases and may serve as an entry point for interventions preventing PND. The proposed project is a large-scale clinical trial to test the effectiveness of a mindfulness-based sleep program designed for pregnant women to improve sleep and alleviate cognitive arousal to reduce risk for PND across pregnancy and postpartum.

Eligibility Criteria

Inclusion Criteria: 1. Singleton pregnancy, gestational week 14-31 at screening. 2. DSM-5 Insomnia Disorder (≥1 month duration). 3. Insomnia Severity Index (ISI) score ≥ 11. 4. Edinburgh Postnatal Depression Scale score\<13 at screening. 5. No current DSM-5 Major Depression. 6. Reliable internet access for treatment and assessments. 7. Not currently engaged in therapy for major depression or insomnia disorder. 8. Age 18 years or older. Exclusion Criteria: 1. High risk pregnancy (pre-eclampsia, placenta previa w/ hemorrhage, other conditions deemed serious risk to mother or fetus; hypertension and diabetes are allowed). 2. Active suicidal intent. 3. Night or rotating shift work, anticipated travel across time 3 or more time zones in the 2 months after baseline screening. 4. Untreated RLS (treated RLS is OK). 5. Excessive daytime sleepiness; Epworth Sleepiness Scale\>15. 6. Uncontrolled sleep or mental disorder inappropriate or unsafe for sleep restriction (narcolepsy, bipolar, epilepsy,

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology